What are the best tools and scoring systems for follow‑up and review of chronic spontaneous urticaria (CSU) patients in a dermatology clinic?

Best Tools and Scoring Systems for CSU Follow-Up in Dermatology Clinics

Use the Urticaria Control Test (UCT) as your primary tool for monitoring disease control in all CSU patients with wheals, and add the Angioedema Control Test (AECT) for patients who experience angioedema—these validated instruments should guide your treatment decisions at every visit. 1

Core Assessment Framework

The 2022 international guidelines emphasize a structured approach requiring assessment of three distinct domains at every visit (initial and all follow-ups):

1. Disease Activity Assessment

For patients with wheals (with or without angioedema):

• 7-Day Urticaria Activity Score (UAS7) - Maximum score of 42 points
  • Daily scoring of wheals: 0 (none), 1 (<20 wheals/24h), 2 (20-50 wheals/24h), 3 (>50 wheals or large confluent areas)
  • Daily scoring of pruritus: 0 (none), 1 (mild/not troublesome), 2 (moderate/interferes with activity), 3 (severe/interferes with sleep or daily activities)
  • Sum scores over 7 consecutive days 1

For patients with angioedema:

• Use the Angioedema Activity Score in combination with UAS7 if wheals are also present 1

2. Disease Control Assessment (Most Critical for Treatment Decisions)

Urticaria Control Test (UCT) - Use for all patients with wheals ± angioedema:

• 4 questions, 5 answer options each
• Cutoff: ≥12 points = well-controlled; <12 points = poorly controlled
• Assesses: physical symptoms, quality of life impact, treatment adequacy, overall control over past 4 weeks
• This score should directly guide your treatment escalation decisions 1

Angioedema Control Test (AECT) - Add for patients with angioedema:

• 4 questions similar to UCT format
• Cutoff: ≥10 points = well-controlled
• Two versions available: 4-week or 3-month recall period
• Use both UCT and AECT if patient has wheals and angioedema 1

3. Quality of Life Impact Assessment

For patients with wheals only:

• Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) 1

For patients with angioedema (with or without wheals):

• Angioedema Quality of Life Questionnaire 1

Use both instruments if patient experiences both wheals and angioedema 1

Clinical Implementation Algorithm

At Every Visit:

1. Administer UCT (and AECT if angioedema present) - takes <2 minutes
2. Review 7-day patient diary for UAS7 calculation
3. Apply quality of life questionnaire appropriate to presentation
4. Make treatment decisions based on control scores:
   • UCT <12 or AECT <10 → escalate treatment per guideline algorithm
   • UCT ≥12 and AECT ≥10 → maintain current therapy
   • Target: complete disease control (UCT = 16) 1

The "7 Cs" Diagnostic Framework for Comprehensive Follow-Up:

1. Confirmation - Rule out differential diagnoses
2. Causes - Look for underlying triggers
3. Cofactors - Identify disease activity modifiers
4. Comorbidities - Check for associated conditions (autoimmunity, mental health)
5. Consequences - Assess impact on sleep, sexual health, social performance
6. Components - Monitor for chronic inducible urticaria development
7. Course - Track activity, impact, and control over time 1

Key Advantages of These Tools

All recommended instruments are:

• Validated patient-reported outcome measures (PROMs)
• Available in multiple languages
• Free of charge for clinical practice
• Easy to administer (4 questions for control tests)
• Have clearly defined cutoffs for clinical decision-making 1

Critical Pitfalls to Avoid

Don't rely on physician global assessment alone - Research shows poor agreement between physician-assessed control (PhyGA) and patient-reported UCT scores (κ = 0.208), while UCT and UAS7 show moderate agreement (κ = 0.581). Patient-reported measures are more accurate 2.

Don't confuse UAS7 versions - Two versions exist (UAS7 and UAS7TD). The standard UAS7 is recommended as it's less burdensome while providing comparable results (correlation r = 0.90) 3.

Don't accept partial control - The guideline emphasizes that complete disease control is the primary treatment goal, not just symptom reduction. Most patients require treatment adjustments to achieve this 1.

Evidence Strength

These recommendations come from the 2022 international urticaria guidelines published in the Journal of Allergy and Clinical Immunology, representing the most current expert consensus 1. Real-world data from the global CURE registry (2078 patients) confirms that achieving complete control (UCT = 16) strongly correlates with better sleep and quality of life outcomes 2.